Daymark Wealth Partners LLC Lowers Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Daymark Wealth Partners LLC decreased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 15.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 295 shares of the biopharmaceutical company’s stock after selling 52 shares during the quarter. Daymark Wealth Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $310,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. DE Burlo Group Inc. grew its position in Regeneron Pharmaceuticals by 7.4% in the second quarter. DE Burlo Group Inc. now owns 8,690 shares of the biopharmaceutical company’s stock worth $9,133,000 after acquiring an additional 600 shares in the last quarter. Decatur Capital Management Inc. increased its position in shares of Regeneron Pharmaceuticals by 2.6% during the 2nd quarter. Decatur Capital Management Inc. now owns 2,674 shares of the biopharmaceutical company’s stock valued at $2,810,000 after purchasing an additional 69 shares during the last quarter. APG Asset Management US Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 2.4% during the 2nd quarter. APG Asset Management US Inc. now owns 31,376 shares of the biopharmaceutical company’s stock valued at $33,165,000 after buying an additional 737 shares in the last quarter. AQR Capital Management LLC lifted its position in Regeneron Pharmaceuticals by 3.7% in the 2nd quarter. AQR Capital Management LLC now owns 189,291 shares of the biopharmaceutical company’s stock worth $198,572,000 after buying an additional 6,839 shares during the last quarter. Finally, Caxton Associates LP bought a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $1,209,000. 83.31% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total value of $105,924.00. Following the sale, the director now owns 17,882 shares in the company, valued at approximately $18,941,329.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, VP Jason Pitofsky sold 487 shares of the company’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the transaction, the vice president now owns 4,204 shares in the company, valued at approximately $4,498,280. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the sale, the director now directly owns 17,882 shares in the company, valued at $18,941,329.68. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 9,270 shares of company stock worth $10,695,833. 7.48% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Trading Up 0.3 %

NASDAQ REGN opened at $1,042.69 on Friday. The firm has a market capitalization of $114.95 billion, a PE ratio of 30.80, a P/E/G ratio of 3.57 and a beta of 0.12. The stock’s 50 day moving average is $1,128.91 and its 200 day moving average is $1,035.02. Regeneron Pharmaceuticals, Inc. has a twelve month low of $769.19 and a twelve month high of $1,211.20. The company has a quick ratio of 4.62, a current ratio of 5.44 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. The firm had revenue of $3.55 billion for the quarter, compared to analysts’ expectations of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The company’s quarterly revenue was up 12.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $8.79 EPS. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have commented on REGN shares. Barclays lifted their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Leerink Partners reissued a “market perform” rating and issued a $1,077.00 price target (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. JPMorgan Chase & Co. raised their price objective on Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. BMO Capital Markets reissued an “outperform” rating and issued a $1,300.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. Finally, Leerink Partnrs lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. One analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,118.62.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.